Key result
Long-term treatment with riociguat reduced mean right ventricular area by 5.9 cm2 at 12 months in patients with PAH and CTEPH.
Why the study?
Does riociguat improve right heart size and function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension?
Cohort (n=39)
Yes
Does riociguat improve right heart size and function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension?
Long-term treatment with riociguat significantly reduces right heart size and improves right ventricular function in patients with PAH and CTEPH.
Answers are grounded in this paper and cite their sources.
Riociguat was associated with reduced RV area in PAH/CTEPH; leaves open need for randomized confirmation before practice change.
BACKGROUND: Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The objective of this study was to evaluate the change of right heart size and function assessed by echocardiography during long-term treatment with riociguat. METHODS: We assessed patients who started riociguat treatment (1.0-2.5mg tid) within the trials PATENT, PATENTplus, EAS and CHEST and continued for 3-12 months. Echocardiography, 6-minute walking distance (6MWD) and further clinical parameters were analyzed at baseline, after 3, 6 and 12 months. Right heart catheterization was performed at baseline and after 3 months. For missing data we performed the last and baseline observation carried forward (LOCF, BOCF) method as sensitivity analyses. RESULTS: Thirty-nine patients (21 PAH, 18 CTEPH, mean pulmonary arterial pressure 43 ± 2 mmHg, PVR 600 ± 43 dyn ∗ s ∗ cm(-5), 56.4% treatment-naïve) were included. Mean right ventricular (RV) area significantly decreased after 3 (-2.1 ± 3.9 cm(2), equals -7.4 ± 15.3%, p = 0.002), 6 (-4.2 ± 3.2 cm(2), equals -16.1 ± 11.5%, p < 0.001) and 12 months (-5.9 ± 4.6 cm(2), equals -22.1 ± 14.2%, p < 0.001) compared to baseline. Right atrial area significantly decreased after 12 months (-3.5 ± 4.1cm(2), equals -16.8 ± 19.2%, p < 0.001) and TAPSE significantly improved after 6 (+ 2 ± 4.7, equals 12 ± 25.8%, p = 0.025) and 12 months (+ 3.6 ± 5.4, equals 21.0 ± 29.6%, p = 0.002). Furthermore, RV wall thickness and 6MWD significantly improved after 3, 6 and 12 months (p < 0.05). Invasive hemodynamics significantly improved after 3 months. Both LOCF and BOCF showed similar significance and lower effect sizes. CONCLUSION: Long-term treatment with riociguat significantly reduced right heart size and improved RV function in PAH and CTEPH. Further prospective studies are needed to confirm these results.
No takes yet. Share an insight, caveat, or question.
Marra et al. (2015) conducted a cohort in Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) (n=39). Riociguat vs. Baseline was evaluated on Change in mean right ventricular (RV) area at 12 months (MD -5.9 cm2, p=<0.001). Long-term treatment with riociguat reduced mean right ventricular area by 5.9 cm2 at 12 months in patients with PAH and CTEPH.
Synapse has enriched 10 related papers. Consider them for comparative context: